Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
Akari Therapeutics PLC AKTX
$7.02
▼ -8.36%
($-0.64)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$7.83
Prev Close
$7.66
Day Range
$6.91 – $7.84
52W Range
$3.02 – $29.32
Market Cap
$13.41M
Beta
1.52
EPS (TTM)
$0.00
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-01-31 |
| Shares Out. | 4,570,330,000 |
| Website | akaritx.com/ ↗ |
| Phone | 19292747510 |
| Employees | 5 |
| Net Income | -$17.3M |
| Free Cash Flow | -$10.8M |
| Total Assets | $47.9M |
| Total Liabilities | $19.6M |
| Equity | $28.3M |
About Akari Therapeutics PLC
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Akari Therapeutics PLC is a publicly traded company under the ticker symbol AKTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-11-01)